Top ▲
Gene and Protein Information | ||||||
class A G protein-coupled receptor | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 7 | 358 | 14q12 | LTB4R2 | leukotriene B4 receptor 2 | 8,12,18 |
Mouse | 7 | 360 | 14 C3 | Ltb4r2 | leukotriene B4 receptor 2 | 7 |
Rat | 7 | 358 | 15p13 | Ltb4r2 | leukotriene B4 receptor 2 | |
Gene and Protein Information Comments | ||||||
In humans, a longer form of BLT2 is 389 amino acids long. |
Previous and Unofficial Names |
BLTR2 | LTB4 receptor JULF2 | LTB4-R2 | 12-HHT receptor | NOP9 |
Database Links | |
Specialist databases | |
GPCRdb | lt4r2_human (Hs), lt4r2_mouse (Mm), lt4r2_rat (Rn) |
Other databases | |
Alphafold | Q9NPC1 (Hs), Q9JJL9 (Mm), Q924U0 (Rn) |
ChEMBL Target | CHEMBL3191 (Hs) |
Ensembl Gene | ENSG00000213906 (Hs), ENSMUSG00000040432 (Mm), ENSRNOG00000020382 (Rn) |
Entrez Gene | 56413 (Hs), 57260 (Mm), 114098 (Rn) |
Human Protein Atlas | ENSG00000213906 (Hs) |
KEGG Gene | hsa:56413 (Hs), mmu:57260 (Mm), rno:114098 (Rn) |
OMIM | 605773 (Hs) |
Pharos | Q9NPC1 (Hs) |
RefSeq Nucleotide | NM_019839 (Hs), NM_020490 (Mm), NM_053640 (Rn) |
RefSeq Protein | NP_062813 (Hs), NP_065236 (Mm), NP_446092 (Rn) |
UniProtKB | Q9NPC1 (Hs), Q9JJL9 (Mm), Q924U0 (Rn) |
Wikipedia | LTB4R2 (Hs) |
Natural/Endogenous Ligands |
12-epi LTB4 |
12-hydroxyheptadecatrienoic acid |
20-hydroxy-LTB4 |
LTB4 |
12R-HETE |
15S-HETE |
12S-HETE |
12S-HPETE |
Comments: 12-Hydroxyheptadecatrienoic acid is the most potent endogenous agonist |
Potency order of endogenous ligands |
12-hydroxyheptadecatrienoic acid > LTB4 > 12S-HETE = 12S-HPETE > 15S-HETE > 12R-HETE > 20-hydroxy-LTB4 [13,17] |
Download all structure-activity data for this target as a CSV file
Agonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific agonist tables |
Antagonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antagonist Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Currently, LY255283 is used as a BLT2-specific antagonist, but this compound also inhibits BLT1 in a non-competitive manner. [11]. |
Immunopharmacology Comments |
The human BLT2 receptor is the low affinity leukotriene B4 receptor, and may be involved in maintaining intestinal barrier function (leading to colitis) and eosinophilic airway inflammation. BLT2 receptor is considered to be the principal mediator of leukotriene B4 effects in synovial tissues from patients with rheumatoid arthritis [3]. |
Immuno Process Associations | ||
|
Immuno Disease Associations | ||||||||||
|
Primary Transduction Mechanisms | |
Transducer | Effector/Response |
Gi/Go family | Adenylyl cyclase inhibition |
References: 8,12,18 |
Secondary Transduction Mechanisms | |
Transducer | Effector/Response |
Gq/G11 family | Phospholipase C stimulation |
References: 8,12,18 |
Tissue Distribution | ||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
Expression Datasets | |
|
Functional Assays | ||||||||||
|
||||||||||
|
||||||||||
|
Physiological Functions | ||||||||
|
||||||||
|
||||||||
|
Physiological Consequences of Altering Gene Expression | ||||||||||
|
||||||||||
|
||||||||||
|
Phenotypes, Alleles and Disease Models | Mouse data from MGI | ||||||||||||||||||||||||||||||
|
Biologically Significant Variants | ||||||||
|
General Comments |
The open reading frame of BLT2 was identified during the analysis of the promoter of BLT1, a high affinity receptor for leukotriene B4 [16]. HEK and CHO cells trasnfected with BLT2 cDNA exhibited a low affinity to LTB4, thus this receptor was named as BLT2 [18]. BLT2 was also activated by various other hydroxy fatty acids including 12-epi LTB4, 12S-HETE and 15S-HETE [17]. Search for endogenous high affinity ligands for BLT2 resulted in the identification of 12-HHT (12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid), previously known as a by-product of thromboxane A2 biosynthesis, as a high-affinity BLT2 ligand [13]. BLT2 is expressed ubuiquitously in human [18], and in small intestine, colon and skin in mice [7]. Mice deficient in both BLT1 and BLT2 showed reduced disease severity in an arthritis model [14]. BLT2-deficient mice with intact BLT1 showed more severe colitis induced by dextran sulfate, possibly due to the loss of intestinal barrier function maintained by BLT2 [6]. BLT2-deficient mice also showed severe eosinophilic inflammation induced by sensitization and elicitation by ovalubumin accompanied by the reduced accumulation of interleukin-13 in the allergic airway [11]. |
1. Bevan S, Dichgans M, Wiechmann HE, Gschwendtner A, Meitinger T, Markus HS. (2008) Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations. Stroke, 39 (4): 1109-14. [PMID:18323512]
2. Bäck M, Bu DX, Bränström R, Sheikine Y, Yan ZQ, Hansson GK. (2005) Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA, 102 (48): 17501-6. [PMID:16293697]
3. Hashimoto A, Endo H, Hayashi I, Murakami Y, Kitasato H, Kono S, Matsui T, Tanaka S, Nishimura A, Urabe K et al.. (2003) Differential expression of leukotriene B4 receptor subtypes (BLT1 and BLT2) in human synovial tissues and synovial fluid leukocytes of patients with rheumatoid arthritis. J Rheumatol, 30 (8): 1712-8. [PMID:12913925]
4. Herron DK, Goodson T, Bollinger NG, Swanson-Bean D, Wright IG, Staten GS, Thompson AR, Froelich LL, Jackson WT. (1992) Leukotriene B4 receptor antagonists: the LY255283 series of hydroxyacetophenones. J Med Chem, 35 (10): 1818-28. [PMID:1316967]
5. Houard X, Ollivier V, Louedec L, Michel JB, Bäck M. (2009) Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. FASEB J, 23 (5): 1376-83. [PMID:19136615]
6. Iizuka Y, Okuno T, Saeki K, Uozaki H, Okada S, Misaka T, Sato T, Toh H, Fukayama M, Takeda N et al.. (2010) Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J, 24 (12): 4678-90. [PMID:20667973]
7. Iizuka Y, Yokomizo T, Terawaki K, Komine M, Tamaki K, Shimizu T. (2005) Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J Biol Chem, 280 (26): 24816-23. [PMID:15866883]
8. Kamohara M, Takasaki J, Matsumoto M, Saito T, Ohishi T, Ishii H, Furuichi K. (2000) Molecular cloning and characterization of another leukotriene B4 receptor. J Biol Chem, 275 (35): 27000-4. [PMID:10889186]
9. Kim GY, Lee JW, Cho SH, Seo JM, Kim JH. (2009) Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler Thromb Vasc Biol, 29 (6): 915-20. [PMID:19286633]
10. Mathis SP, Jala VR, Lee DM, Haribabu B. (2010) Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis. J Immunol, 185 (5): 3049-56. [PMID:20656922]
11. Matsunaga Y, Fukuyama S, Okuno T, Sasaki F, Matsunobu T, Asai Y, Matsumoto K, Saeki K, Oike M, Sadamura Y et al.. (2013) Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia. FASEB J, 27 (8): 3306-14. [PMID:23603839]
12. Nilsson NE, Tryselius Y, Owman C. (2000) Genomic organization of the leukotriene B(4) receptor locus of human chromosome 14. Biochem Biophys Res Commun, 274 (2): 383-8. [PMID:10913347]
13. Okuno T, Iizuka Y, Okazaki H, Yokomizo T, Taguchi R, Shimizu T. (2008) 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med, 205 (4): 759-66. [PMID:18378794]
14. Shao WH, Del Prete A, Bock CB, Haribabu B. (2006) Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J Immunol, 176 (10): 6254-61. [PMID:16670336]
15. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. (2004) Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol, 24 (2): 369-75. [PMID:14656734]
16. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. (1997) A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature, 387 (6633): 620-4. [PMID:9177352]
17. Yokomizo T, Kato K, Hagiya H, Izumi T, Shimizu T. (2001) Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem, 276 (15): 12454-9. [PMID:11278893]
18. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. (2000) A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med, 192 (3): 421-32. [PMID:10934230]